Latest News
- October 10th 2011: Daval International announces positive Phase II results for AIMSPRO® as a monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
- June 2011 : Daval International announces completion of Phase II Trial in Multiple Sclerosis
- February 20th 2011 : Daval International announces completion of Phase II Trial evaluating the safety and efficacy of AIMSPRO® in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) at Royal Free Hospital in London
- October 6th 2010 : Daval International and Idis partner to facilitate access to AIMSPRO®, through Named Patient Programme
- 1st October 2010 : Professor Syed Haq MBBS BSc PhD DIC MRCP(UK) joins Daval International Board of Directors as Chief Scientific Officer